Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MindBio Therapeutics Corp C.MBIO

MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.


CSE:MBIO - Post by User

Post by Smokey1958on May 14, 2024 10:03am
126 Views
Post# 36038576

Why Would Enveric Do This?

Why Would Enveric Do This?The potential in this is extraordinary for both companies.

I would expect that the reasons for Enteric entering into an agreement like this is that they have a much faster path to clinical trials for their patented drugs and system. By the time they could get FDA approval MBIO could be on to the second phase of trials.

As for MBIO the most significant challenge would be cash to carry out trials for a different drug candidate. The fact that they're expressing payback through royalties etc in the $60+ million range suggests there is strong belief in the relationship.

As for the cash buyout ...does it refer to the potential for MBIO to ultimately buy out Enteric? It looks to me like Justin and the rest of the Board of MBIO has their hands solidly on the wheel.

Regardless, this is the kind of exponential development seen in this clinical trials stage of MBIO.
<< Previous
Bullboard Posts
Next >>